--- title: "Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% Higher - Here's Why" type: "News" locale: "en" url: "https://longbridge.com/en/news/296134128.md" description: "Kailera Therapeutics (NASDAQ:KLRA) shares rose 6.6% to $19.13 on Monday, despite trading volume being 51% below average. The stock's movement coincides with a wave of analyst coverage initiated on May 12 by Jefferies, Leerink Partners, William Blair, and Evercore, all issuing 'buy' or 'outperform' ratings with price targets ranging from $36 to $48. Zacks Research upgraded the stock to 'hold'. The consensus rating is 'Buy' with an average target price of $42.75." datetime: "2026-08-17T17:40:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296134128.md) - [en](https://longbridge.com/en/news/296134128.md) - [zh-HK](https://longbridge.com/zh-HK/news/296134128.md) generator: "portal-rs" --- # Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% Higher - Here's Why Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) were up 6.6% during trading on Monday . The stock traded as high as $19.21 and last traded at $19.13. Approximately 341,212 shares were traded during mid-day trading, a decline of 51% from the average session volume of 700,079 shares. The stock had previously closed at $17.94. Get **Kailera Therapeutics** alerts: ## Analyst Ratings Changes KLRA has been the topic of a number of analyst reports. Jefferies Financial Group began coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a "buy" rating and a $48.00 price target on the stock. Leerink Partners initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an "outperform" rating and a $36.00 price objective for the company. William Blair began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an "outperform" rating on the stock. Evercore assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an "outperform" rating on the stock. Finally, Zacks Research upgraded shares of Kailera Therapeutics to a "hold" rating in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $42.75. **View Our Latest Analysis on Kailera Therapeutics** ## Kailera Therapeutics Price Performance The firm has a market cap of $2.48 billion and a price-to-earnings ratio of -0.01. The stock has a 50-day moving average of $19.43. Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). Sell-side analysts anticipate that Kailera Therapeutics, Inc. will post -3.63 EPS for the current fiscal year. ## Kailera Therapeutics Company Profile (Get Free Report) We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. ## Further Reading - Five stocks we like better than Kailera Therapeutics - This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem - Birkenstock Beats the Skeptics—But Not on EPS - D-Wave Has Momentum—What Does It Need to Keep It Going? - TSMC’s Insider Buying Wave Comes With a Bigger AI Question for Investors *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Kailera Therapeutics Right Now? Before you consider Kailera Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kailera Therapeutics wasn't on the list. While Kailera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [KLRA.US](https://longbridge.com/en/quote/KLRA.US.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [EVR.US](https://longbridge.com/en/quote/EVR.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [BIRK.US](https://longbridge.com/en/quote/BIRK.US.md) - [QBTS.US](https://longbridge.com/en/quote/QBTS.US.md) - [TSM.US](https://longbridge.com/en/quote/TSM.US.md) - [QBTS+.US](https://longbridge.com/en/quote/QBTS+.US.md) ## Related News & Research - [2 GLP-1 Stocks That Could Double Your Money by 2031](https://longbridge.com/en/news/296030914.md) - [Wrap Technologies (NASDAQ: WRAP) Selected to Support Florida Teacher Safety Training Program](https://longbridge.com/en/news/296129490.md) - [Joanne Donovan Sells 2,919 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock](https://longbridge.com/en/news/295978695.md) - [This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/en/news/296231890.md) - [Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/296450253.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**